Form 4: Coya Therapeutics Director Howard Berman Acquires Stock Options

Director Howard Berman of Coya Therapeutics acquired 150,602 stock options on January 9, 2025, which vest over 36 months.

Summary

• Howard Berman, a director at Coya Therapeutics, acquired 150,602 stock options on January 9, 2025.
• The options have an exercise price of $6.07 per share.
• The options will vest in monthly installments over 36 months, starting on February 9, 2025.
• The vesting is contingent upon continuous service on each vesting date.
• The options expire on January 9, 2035.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is neither particularly positive nor negative. It is a neutral event from an investment perspective.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Risks

• The vesting of the options is contingent on continuous service, which could be a risk if the director leaves the company before all options are vested.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation packages.
• The vesting schedule of 36 months is also a typical arrangement to incentivize long-term commitment from directors.
• The exercise price of $6.07 is a specific value for this grant and would need to be compared to other grants to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could be seen positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, director, Coya Therapeutics, equity, vesting